Penumbra/$PEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Penumbra
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Ticker
$PEN
Sector
Primary listing
NYSE
Employees
4,700
Headquarters
Website
Penumbra Metrics
BasicAdvanced
$13bn
73.29
$4.34
0.74
-
Price and volume
Market cap
$13bn
Beta
0.74
52-week high
$362.41
52-week low
$221.26
Average daily volume
394k
Financial strength
Current ratio
6.024
Quick ratio
3.773
Long term debt to equity
13.546
Total debt to equity
14.668
Interest coverage (TTM)
143.29%
Profitability
EBITDA (TTM)
203.963
Gross margin (TTM)
67.38%
Net profit margin (TTM)
11.76%
Operating margin (TTM)
12.87%
Effective tax rate (TTM)
15.72%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
6.70%
Return on equity (TTM)
12.73%
Valuation
Price to earnings (TTM)
73.294
Price to revenue (TTM)
8.548
Price to book
8.48
Price to tangible book (TTM)
9.61
Price to free cash flow (TTM)
58.434
Free cash flow yield (TTM)
1.71%
Free cash flow per share (TTM)
5.441
Growth
Revenue change (TTM)
17.27%
Earnings per share change (TTM)
302.41%
3-year revenue growth (CAGR)
18.02%
10-year revenue growth (CAGR)
21.64%
3-year earnings per share growth (CAGR)
194.03%
10-year earnings per share growth (CAGR)
40.72%
What the Analysts think about Penumbra
Analyst ratings (Buy, Hold, Sell) for Penumbra stock.
Penumbra Financial Performance
Revenues and expenses
Penumbra Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.